Continuing clozapine treatment with lithium in schizophrenic patients with neutropenia or leukopenia: brief review of literature with case reports
THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY, cilt.6, sa.1, ss.33-38, 2016 (SCI-Expanded)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 6 Sayı: 1
- Basım Tarihi: 2016
- Doi Numarası: 10.1177/2045125315624063
- Dergi Adı: THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED)
- Sayfa Sayıları: ss.33-38
- Anahtar Kelimeler: clozapine, leukopenia, lithium, neutropenia, treatment-resistant, schizophrenia, INDUCED AGRANULOCYTOSIS, RESISTANT SCHIZOPHRENIA, BLOOD DYSCRASIAS, SAFETY, TRIAL, RECHALLENGE, PREVENTION, THERAPY
- Süleyman Demirel Üniversitesi Adresli: Hayır
Özet
Objective: Clozapine is a second-generation antipsychotic used for treatment-resistant schizophrenia. Despite its effectiveness, clozapine is largely underused due to serious side effects such as leukopenia or neutropenia. We aimed to review whether to continue, discontinue or rechallenge clozapine treatment after such haematological side effects.